Last reviewed · How we verify
Simplified intensive insulin therapy regimen
A simplified insulin dosing regimen that delivers basal and bolus insulin in a more streamlined manner to improve glycemic control in diabetes patients.
A simplified insulin dosing regimen that delivers basal and bolus insulin in a more streamlined manner to improve glycemic control in diabetes patients. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring insulin therapy.
At a glance
| Generic name | Simplified intensive insulin therapy regimen |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Endocrinology/Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a therapeutic regimen rather than a molecular drug, designed to optimize insulin delivery through a simplified protocol that reduces complexity while maintaining efficacy. The approach typically combines long-acting basal insulin with rapid-acting bolus insulin at meals, but with fewer injections or simplified dosing algorithms compared to standard intensive regimens. The goal is to improve patient adherence and glycemic outcomes while reducing the burden of complex insulin management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus requiring insulin therapy
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: